Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune checkpoint inhibitor atezolizumab to carbo/paclitaxel/bevacizumab in patients ...
Author: BeaconMedIC
Added: 12/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 18, 2017 Category: Cancer & Oncology Source Type: podcasts
IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma
Sumanta Kumar Pal, M.D City of Hope Cancer Center discusses IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevac...
Author: kidneycancer
Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts
Discussion of Correlatives Associated with Presurgical Nivolumab + - Bevacizumab or Ipilimumab Trial in mccRCC
Discussion of Correlatives Associated with Presurgical Nivolumab + - Bevacizumab or Ipilimumab Trial i...
Author: kidneycancer
Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Correlatives Associated with Bevacizumab/Atezolizumab
Walter Stadler, MD of The University of Chicago discusses the Correlatives Associated with Bevacizumab/Atezolizumab at the annual 2017 Kidney Cancer Association symposium in Miami, FL
Author: kidneycancer
Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2017 Category: Cancer & Oncology Source Type: podcasts
Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Either bevacizumab or EGFR antibodies
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-t...
Author: imedex
Added: 10/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Final Results of the TAVAREC Trial: Temozolomide with or without Bevacizumab in Glioma
Daniela Bota, MD of UC Irvine Health gives an overview of the final results of the TAVAREC trial, which studied temozolomide and bevacizumab in patients with glioma. This was recorded at the 2017 MOAS...
Author: moasc
Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts
AvaALL: Bevacizumab Beyond Progression in Patients with Metastatic Non-Squamous NSCLC
Viola Zhu, MD, PhD of UC Irvine Health discusses the AvaALL trial and the use of bevacizumab beyond progression in patients with non-small cell lung cancer. This was recorded at the 2017 MOASC Spotlig...
Author: moasc
Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Use of Atezolizumab, Bevacizumab, and Sunitinib in Kidney Cancer
Sarmen Sarkissian, MD of UC Irvine Health discusses the highlights in kidney cancer research specifically a phase II study on the use of Atezolizumab and Bevacizumab for patients with locally advanced...
Author: moasc
Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat the blood vessels and reduce the swelling. In June 2017, Gianni Virgili from the University of Florence in Italy, and colleagues, updated their Cochrane review of these drugs and used a network meta-analysis to compare their effects. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - July 12, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat the blood vessels and reduce the swelling. In June 2017, Gianni Virgili from the University of Florence in Italy, and colleagues, updated their Cochrane Review of these drugs and used a network meta-analysis to compare their effects. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - July 12, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat the blood vessels and reduce the swelling. In June 2017, Gianni Virgili from the University of Florence in Italy, and colleagues, updated their Cochrane Review of these drugs and used a network meta-analysis to compare their effects.Note: The latest version of this review has been published on October 2018 but the conclusions as outlined in this podcast have not changed. (Source: Po...
Source: Podcasts from The Cochrane Library - July 12, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
David McDermott, MD of Dana-Farber Cancer Center discusses the Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients at the 12...
Author: kidneycancer
Added: 04/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Ovarian Cancer Treatment Trends for 2017 Includes Chemotherapy, PARP Inhibitors, and Bevacizumab
Don Dizon, MD of Massachusetts General Hospital gives an overview of the treatment trends for 2017 in ovarian cancer treatment, which were discussed at the 2017 Society of Gynecologic Oncology (SGO)s...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Cul es el rol de Avastin (bevacizumab) en el tratamiento del cncer de pulmn de clulas no pequeas en la actualidad?
What is the role of Avastin (bevacizumab) in treating advanced NSCLC today?
Author: cancergrace
Added: 12/07/2016 (Source: Oncology Tube)
Source: Oncology Tube - December 7, 2016 Category: Cancer & Oncology Source Type: podcasts
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) vs standard of care
Thomas Hutson, Memorial Sloan Kettering Cancer Center, New York, NY presents A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRC...
Author: kidneycancer
Added: 11/07/2016 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2016 Category: Cancer & Oncology Source Type: podcasts
